At Mylan, Epi-penance is transparent on actions, opaque on reasons
| |

At Mylan, Epi-penance is transparent on actions, opaque on reasons

ByJosh Bernoff

Mylan and its CEO Heather Bresch are under fire. It raised the price of its EpiPen product — an essential protection for people with life threatening allergies — by a factor of five in the last eight years. Mylan’s statement defending itself clarifies what it’s doing — providing rebates — but evades the main issue of…

Turing CEO Martin Shkreli reveals how passive voice is the last refuge of a scoundrel
| |

Turing CEO Martin Shkreli reveals how passive voice is the last refuge of a scoundrel

ByJosh Bernoff

Martin Shkreli, the CEO of Turing Pharmaceuticals, announced a huge increase in the cost of his drug for a life-threatening disease. Then he backtracked. By analyzing his passive statements, you see exactly how a scoundrel evades responsibility. After acquiring the drug Daraprim, used to treat the sometimes deadly parasitic infection toxoplasmosis, Turing Pharmaceuticals hiked the price from $13.50 to…